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Abstract: The metabotropic glutamate receptor family comprises eight subtypes (mGlu1-8) of G-protein coupled receptors. mGlu recep-
tors have a large extracellular domain which acts as recognition domain for the natural agonist glutamate. In contrast to the ionotropic 
glutamate receptors which mediate the fast excitatory neurotransmission, mGlu receptors have been shown to play a more modulatory 
role and have been proposed as alternative targets for pharmacological interventions. The potential use of mGluRs as drug targets for 
various nervous system pathologies such as anxiety, depression, schizophrenia, pain or Parkinson’s disease has triggered an intense 
search for subtype selective modulators and resulted in the identification of numerous novel pharmacological agents capable to modulate 
the receptor activity through an interaction at an allosteric site located in the transmembrane domain. The present review presents the 
most recent developments in the identification and the characterization of allosteric modulators for the mGlu receptors. 
INTRODUCTION 
  Since their identification in the mid eighties [56] and their sub-
sequent cloning [18,31] in the early nineties, the metabotropic glu-
tamate receptor (mGluR) family triggered an intensive search to-
ward the identification of pharmacological agents to determine the 
role of the mGlu receptors in the nervous system physiology and 
patho-physiology. To date eight of such receptors (mGlu1-8) have 
been cloned and based on their amino-acids sequence, pharmacol-
ogy and second messenger coupling these receptors have been clus-
tered into three groups (I - III) [4]. mGlu receptors belong to the 
family 3 GPCRs and as such have a large extracellular ligand rec-
ognition N-terminal domain and seven transmembrane-spanning 
regions that are connected by three intra-cellular and three extracel-
lular loops with a number of conserved cysteine residues [16]. The 
extracellular ligand recognition N-terminal domain has a so-called 
bi-lobed structure (= Venus fly-trap function) that can adopt an 
open or closed configuration in the absence or presence of an ago-
nist, respectively [41]. In addition, there are indications that in the 
brain functional mGlu1 and mGlu5 receptors may predominantly 
exist as homodimers [52]. Glutamate is the physiological agonist 
for all mGlu receptors subtypes and as such the first selective 
agents identified were glutamate analogs [54] and are acting at the 
receptor by displacing Glutamate from its binding site located in the 
N-terminal domain, the orthosteric site. As such those ligands are 
named competitive agonists or antagonists. The structural analogy 
to Glutamate, with the presence of a distal carboxylic acid to the 
amino-acid functionality, strongly influence the properties of the 
competitive ligands and limits considerably their capacity to cross 
membranes by passive diffusion. As a consequence, these com-
pounds have a poor oral bioavailability, and do not readily cross the 
blood-brain-barrier. A noticeable exception is illustrated by the 
small molecular weight ligands, LY354740, LY379268 or 
LY404039 [53] which display potent agonist activity at mGlu2/3 
receptors, are orally bioavailable, and enter the brain in preclinical 
model [36,37] and have been developed throughout the clinic as 
potential anti-panic agents [2]. 
  The difficulty to identify suitable glutamate analog with ade-
quate drug-like properties and subtype selectivity has been an im-
portant element that fostered the search for alternative structural 
compound classes to inhibit or activate mGlu receptor function.  
DISCOVERY 
  The identification of the allosteric modulators is intimately 
linked with the development of in vitro assays allowing the charac-
terization of the functional activity of agents acting at the receptor. 
For the Group I mGlu receptors, coupled to Gq type of G-proteins, 
two cellular assays based on IP3 turnover and measurements of 
intracellular Ca
2+ concentration were developed (Fig. 1).
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  For the Group II and III mGlu receptors, which are coupled to 
Gi type of G-proteins, functional assays involving GTP--
35S bind-
ing and determination of cAMP concentration changes were devel-
oped (Fig. 2).
  The development of these functional assays and their adaptation 
to a high throughput screening mode allowed the screening of large 
chemical libraries and the identification of numerous ligands with 
no structural analogies to the natural ligand Glutamate acting as 
negative allosteric modulators (NAM) or as positive allosteric 
modulators (PAM).  
  A number of excellent reviews describing in the mechanism of 
action and the progresses in the allosteric modulator field have been 
published [13,14,20,44,45,50,55]. Here, we would like to describe 
the most recent developments in the identification and characteriza-
tion of allosteric ligands for the various mGluR subtypes.  
GROUP I  
mGluR1 NAM 
 CPCCOEt  (1) was the first non glutamate antagonist described 
for the mGlu1 receptor [1]. This agent has been a useful tool to 
investigate the role of the mGluR1 subtype in vitro, however, its 
limited potency (only low micromolar IC50), its lack of bio-
availability and brain penetration did not allow a broad use in vivo.
Nevertheless, CPCCOEt was identified as non-competitive inhibitor 
and allowed to unravel and characterize the allosteric binding site 
located in the transmembrane domain [28]. A more potent com-
pound, BAY36-7620 (2) was subsequently described to interact at 
the same allosteric binding site and to inhibit the receptor constitu-
tive activity [3]. The improved in vivo properties of BAY36-7620 
has allowed the detection of an early signal for analgesic and anti-
convulsant effect but also for an impaired acquisition of a spatial 
memory task (Morris water maze) [9,58]. This effect on memory 
was later confirmed with highly optimized compounds. However, 
various issues including potency has limited an extensive charac-
terization using this compound for the use of exploring the potential 
of mGlu1 receptor antagonists for the treatment of various CNS 
disorders. The first described highly potent, selective and systemi-
cally active mGlu1 receptor antagonist is JNJ16259685 (3) [25]. 
JNJ16259685 is a non competitive antagonist with IC50 values of 
3.2 and 1.2 nM in glutamate-induced calcium mobilization at rat 
and human receptors, respectively. In addition, systemic application 
of JNJ16259685 resulted in high receptor occupancy at low dosis. 
Together these data provide evidence that JNJ16259685 is an excel-
lent tool to explore the potential of mGlu1 receptor antagonists as 
therapeutics [25]. Steckler et al. [60] described anxiolytic-like 
properties in punished licking behavior which appeared to have 
synergistic effects with mGlu5 receptor antagonists. Nevertheless, 
the effects seem different from those for mGlu5 receptor antago-
nists as prominent effects were only seen on conflict procedures but 
not on task based spontaneous exploration. Effects were described 
on locomotor activity as expected from the expression pattern in 
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tolerance to these motor disturbances. Subsequently, Steckler et al.
[61] described that JNJ16259685 impaired spatial acquisition proc-
esses, irrespective of spatial load, as well as spatial re-acquisition, 
already at the lowest dose tested (0.63 mg/kg). Effects on spatial 
retention performance were relatively mild in mice that had learned 
to locate the position of the escape platform prior to treatment. 
These data suggest that blockade of the mGlu1 receptor primarily 
affects learning of new information, but leaves retention of spatial 
information relatively unaffected. 
  Another potent and selective non-competitive mGlu1 antagonist 
is A-841720 (4) [10]. At recombinant human and native rat 
mGluR1 receptors, A-841720 inhibited agonist-induced calcium 
mobilization, with IC50 values of 10.7 and 1.0 nM, respectively, 
while showing selectivity over other mGluR receptors. Intraperito-
neal injection of A-841720 potently reduced complete Freund's 
adjuvant-induced inflammatory pain (ED50 = 8 mg/kg) and mon-
oiodoacetate-induced joint pain (ED50 = 15 mg/kg). A-841720 also 
decreased mechanical allodynia observed in both the sciatic nerve 
chronic constriction injury and L5-L6 spinal nerve ligation (SNL) 
models of neuropathic pain (ED50 = 10 and 9 mg/kg, respectively). 
Electrophysiological studies demonstrated that systemic administra-
tion of A-841720 in SNL animals significantly reduced evoked 
firing in spinal wide dynamic range neurons. Importantly, signifi-
cant motor side effects were observed at analgesic doses and A-
841720 also impaired cognitive function in the Y-maze and the 
Water Maze tests with no therapeutic index. The analgesic effects 
of a selective mGluR1 receptor antagonist are associated with mo-
tor and cognitive side effects. 
  Taken together, the lack of separation between efficacy and side 
effects in pre-clinical models indicates that mGluR1 antagonism 
may not provide an adequate therapeutic window for the develop-
ment of such antagonists as therapeutics in humans. 
mGluR1 PAM 
 Knoflach  et al. [23] were the first to describe two chemical 
series, compounds 5, 6 and 7 (Fig. 3), capable to potently increase 
agonist-mediated responses in cells expressing the rat mGlu1 recep-
tor and in rat brain tissues. All three compounds were shown to 
enhance the binding affinity of agonists for the orthosteric site. In 
cells recombinantely expressing high level of the receptor and in 
which the receptor shows a significant level of constitutive activity, 
all three compounds were found to elicit a response in the absence 
of orthosteric agonist. No similar effect was seen in native systems. 
From the mechanistically point of view these effects were explained 
by an interaction of the compound with an active form of the recep-
tor and the stabilization thereof. Compounds 5 and 7, showed selec-
tivity over the rmGlu2, rmGlu4, rmGlu5, rmGlu8 and hGABAB
receptors whereas compound 6 displayed a weak activation of the 
glutamate-induced activation at the rmGlu5 receptor. Interestingly, 
when tested on the human mGlu1 receptor only compound 6 acted 
as positive modulator, compounds 5 and 7 being devoid of activity. 
Furthermore, using chimeric receptor constructs and site directed 
mutagenesis, Knoflach et al. [23], could demonstrate that all three 
compounds interact in the transmembrane domain in an overlapping 
pocket compared to the mGluR1 NAMS. Recently, a series of 
structurally different mGlu1 positive modulators obtained by 
chemical derivatization of the mGluR5 PAM CDPPB (15, Fig. 3)
Fig. (1). Group I mGluRs signal transduction pathway.
Fig. (2). Group II and III mGluR signal transduction pathway.
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was described and characterized. In contrast to the compounds 5, 7
and 8, the CDPPB series was shown to interact in the transmem-
brane domain with a different binding mode compared to the 
mGluR1 allosteric negative modulators [8]. 
  So far, no in vivo activity has been reported on the effects of 
mGlu1 receptor PAMs, but based on the negative effects of NAMs 
on learning and memory [10,61] it can be hypothesized that en-
hancement of mGlu1 receptor activity through a selective PAM 
could be beneficial to restore normal learning and memory proc-
esses. 
mGluR5 NAM 
 2-methyl-6-(phenylethynyl)-pyridine  (MPEP),  8 is the proto-
typical allosteric mGlu5 receptor antagonist [12]. It is a potent, 
selective and systemically active antagonist. At the human mGlu5a 
receptor expressed in recombinant cells, MPEP completely inhibits 
quisqualate-stimulated phosphoinositide (PI) hydrolysis with an 
IC50 value of 36 nM while having no agonist or antagonist activities 
at other receptors up to 30 M. Schild's analysis indicated that 
MPEP acts in a non-competitive manner. MPEP also inhibited to a 
large extent constitutive receptor activity in cells transiently over-
expressing rat mGluR5, suggesting that MPEP may act as an in-
verse agonist [40]. 
  Using chimeras and single amino acid substitutions between 
hmGluR1 and hmGluR5, binding of the mGluR5 radioligand [
3H]-
2-methyl-6-(3-methoxyphenyl)ethynyl pyridine (M-MPEP) it could 
be determined that the amino acids Ala-810 (TMVII), Pro-655 and 
Ser-658 (TMIII) of the mGlu5 receptor are necessary to mediate the 
binding and the selectivity of the MPEP series of antagonists. Con-
versely, the introduction of these three amino-acids in the corre-
sponding reciprocal position of the hmGlu1 receptor led to a mutant 
mGlu1 receptor capable to bind [
3H]-M-MPEP with low nanomolar 
affinity [40]. Radioligand binding to these mutants was also inhib-
ited by 7-hydroxyiminocyclopropan [b]chromen-1a-carboxylic acid 
ethyl ester (CPCCOEt), a structurally unrelated non-competitive 
mGluR1 antagonist previously shown to interact within the TM 
region of the mGlu1 receptor [28].These results indicate that MPEP 
and CPCCOEt bind to overlapping binding pockets in the TM re-
gion of group I mGluRs but interact with different non-conserved 
residues. Several additional allosteric mGlu5 antagonists based on 
the chemical structure of MPEP have been described and character-
ized, among those MTEP 9 a close derivative was also extensively 
characterized [5,57]. 
  The identification of MPEP (2-methyl-6-(phenylethynyl)-
pyridine allowed the exploration of the therapeutic potential of this 
class of compounds. Subsequent behavior studies revealed that--
with the exception of benzodiazepines--mGlu5 receptor antagonists 
exhibit the widest and most robust anxiolytic activity in preclinical 
models seen to date [59]. 
Fenobam 
 Fenobam  [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-
1H-imidazole-2-yl)urea] (10) is an atypical anxiolytic agent, with 
until recently an unknown molecular target, that has previously 
been demonstrated both in rodents and human to exert robust anx-
iolytic-like activity. During a HTS screen at F. Hoffmann-La 
Roche, Fenobam (McN-3377) was identified as a potent antagonist 
at mGlu5 receptors [49]. Characterization revealed that Fenobam is 
a selective and potent metabotropic glutamate mGlu5 receptor an-
tagonist acting at an allosteric modulatory site shared with 2-
methyl-6-phenylethynyl-pyridine (MPEP). Fenobam inhibited quis-
qualate-evoked intracellular calcium response mediated by human 
mGlu5 receptor with IC50 = 58 nM. It acted in a noncompetitive 
manner, similar to MPEP and demonstrated inverse agonist proper-
ties, blocking 66% of the mGlu5 receptor basal activity (in an over 
expressed cell line) with an IC50 = 84 nM. [
3H]-Fenobam bound to 
rat and human recombinant receptors with Kd values of 54 and 31 
Fig. (3). mGluR1 allosteric modulators.
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nM, respectively. MPEP inhibited [
3H]-fenobam binding to human 
mGlu5 receptors with a Ki value of 6.7 nM, indicating a common 
binding site shared by both allosteric antagonists. Fenobam exhibits 
robust anxiolytic-like activity with efficacy comparable to MPEP in 
the stress-induced hyperthermia model, Vogel conflict test, Geller-
Seifter conflict test, and conditioned emotional response with a 
minimum effective dose of 10 to 30 mg/kg p.o. Furthermore, Feno-
bam is devoid of GABAergic activity, confirming previous reports 
that Fenobam acts by a mechanism distinct from benzodiazepines. 
The non-GABAergic activity of Fenobam, coupled with its robust 
anxiolytic activity supports the potential of developing mGlu5 re-
ceptor antagonists with an improved therapeutic window over ben-
zodiazepines as novel anxiolytic agents. The confidence in mGlu5 
receptor antagonists as a treatment for anxiety is obviously strongly 
supported by positive results in clinical trials with patients. There 
are at least two positive trials that indicate that Fenobam is indeed 
efficacious in man including a double blind placebo-controlled and 
standardized (Diazepam) trial [42,43]. It was concluded from these 
studies that Fenobam relieved symptoms of anxiety in broad spec-
trum psychoneurotic patients which may experience anxiety as 
cognitive, dysphoric or motor autonomic. The anxiolytic activity is 
differentiated from benzodiazepines and fenobam was safe and 
induced less sedation and drowsiness. Clearly, these findings need 
to be confirmed in upcoming clinical trials using highly optimized 
mGlu5 receptor antagonists but provide great promise for future 
studies. 
mGluR5 PAM 
  In contrast to the high number of NAM for the mGlu5 receptor, 
relatively few positive allosteric modulators have been described. 
The first series of compounds is based on a benzaldazine core struc-
ture and the pharmacological activity is determined by the nature 
and the position of the substituents [38]. In this series, DFB (3,3’-
difluorobenzaldazine, 11, Fig. 5), acts as positive modulator and 
induces a marked increase in glutamate potency (EC50). Interest-
ingly, a change in the nature of the substituent with a replacement 
of the two fluorine atoms by a methoxy group conferred an antago-
nisticactivitytotheresultingDMeOB (3,3’-dimethoxyBenzaldazine, 
12, Fig. 5) derivative. Another very subtle substitution change, 
chlorine for the fluorine atoms, led to the identification of a ligand 
with no functional activity at the receptor, DCB (3,3’-dichloro-
benzaldazine, 13, Fig. 5). The DFB family of modulators is the first 
to demonstrate the whole range of pharmacological activities from 
activation to inactivation of the receptor as well as neutral/silent 
receptor ligands. All active derivatives of this series are interacting 
in the transmembrane domain in a similar but not identical binding 
site to the mGluR5 NAMs of the MPEP structural family. Shortly 
after, two novel, structurally unrelated series illustrated by the pro-
totypic compounds CPPHA (14) and CDPPB (15) were described 
by the same research group [27,39]. Both compounds showed a 
potent increase of agonist mediated receptor activation for both 
human and rat receptors with no cross reactivity at the other mGluR 
subtypes nor at other CNS receptors. No activation of the receptor 
was seen when DFB or CPPHA were used in the absence of orthos-
teric agonist [39] whereas CDPPB alone was capable to induce   
a receptor activation [22]. All three compounds had no effect on  
the binding of the orthosteric ligand [
3H]-quisqualate [22,39] 
whereas only DFB and CDPPB did inhibit the binding of [
3H]-
methoxy-PEP-y [5] a derivative of the allosteric negative modulator 
MPEP. Despite intense medicinal chemistry efforts, neither the 
DFB nor CPPHA series did not deliver suitable molecules for in 
vivo evaluation in preclinical models. In contrast, derivatization of 
the CDPPB series not only allowed the identification more potent 
derivatives but also the identification of mGluR1 positive allosteric 
modulators [8]. 
Fig. (4). mGluR5 allosteric modulators.
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 In  vivo, CDPPB was evaluated in two behavioral models sensi-
tive to antipsychotic: the amphetamine-induced locomotor activity 
and the amphetamine-induced disruption of prepulse inhibition 
(PPI) in rat. In both models, CDPPB showed a dose dependent 
beneficial effect without noticeable side-effects [22]. These results 
demonstrated for the first time the in vivo activity of a selective 
mGluR5 allosteric positive modulator and suggested a potential use 
of these type of modulator as anti-psychotics.  
GROUP II  
mGluR2 NAM 
  Since the publication of two series of mGluR2 NAMs by Kol-
czewski et al. [24] and Wichmann et al. [63] no further develop-
ment nor structurally novel mGluR2 NAMs have been described to 
date. These two series illustrated by the compounds 16 and 17 (Fig. 
4) were shown to inhibit agonist stimulated GTP--[
35S] binding on 
a rat mGluR2 transfected cell membranes with sub-micromolar 
IC50. Both lead compounds were also shown to be selective over 
mGluR1, mGluR4, mGluR5 and ionotropic GluRs but no data was 
published for the selectivity over the mGluR3 or other CNS recep-
tors. Based on the effects achieved with orthosteric antagonists, it 
could be speculated that mGluR2 NAMs could improve cognitive 
and or memory disturbances [17]. 
mGluR2 PAM 
  Among all mGlu receptor subtypes, the activation of the Group 
II subtypes is by far the best studied thanks to the identification and 
development by Eli Lilly of the orthosteric agonist LY354740 
[36,37]. This compound and its prodrug derivative (LY544344) 
have been extensively characterized in preclinical model for anxiety 
related disorders and subsequently developed in the clinic where 
their use demonstrate the usefulness of activation of Group II recep-
tors for the treatment of anxiety related disorders [26]. This proof of 
principle with LY354740 also confirms that activation of the 
mGluR2,3 subtypes display therapeutic activity at doses which are 
devoid of the side effects typically observed with agents interacting 
with the ionotropic glutamate receptors. 
  The search for orthosteric ligands derived from the original 
structure, LY354740, with similar pharmacological and drug- 
like properties proved to be extremely difficult and prompted the 
search for alternative structures. As for the Group I, the use of func-
tional assays combined with the screening of chemical libraries 
allowed the identification of the first series of positive allosteric 
modulators: the sulfonamide derivatives such as LY487379 (18)
[19]. LY487379 and analog compounds from the same chemical 
class were shown to act as allosteric modulators with an activation 
of the receptor only in the presence of an orthosteric agonist and no 
displacement of the orthosteric antagonist LY341495. In contrast to 
all known orthosteric agonists, LY487379 and its derivatives are 
selective for the mGluR2 over the other seven mGluR subtypes 
including the mGluR3 and over a binding battery of CNS relevant 
receptor.  In vivo, LY487379 or its derivatives demonstrated effi-
cacy in animal models for anxiety (Fear potentiated startle; Stress 
induced hyperthermia) or for anti-psychotic activity (PCP induced 
locomotor activity) [21]. A second series of compound was de-
scribed shortly after by a research group at Merck and exemplified 
by the phenyl-tetrazolyl acetophenone derivative 19 (Fig. 5)
[7,46,47,48]. In vitro, this series of compounds showed a similar 
profile to the LY487379 and in vivo the use of a more potent and 
brain penetrable compound, BINA (20), confirmed the potential 
anti-psychotic effects in animal models [11,15,48,51]. 
Fig. (5). mGluR2 allosteric modulators.
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  Taken together these results that mGluR2 selective modulators 
constitute a potential alternative for a pharmacotherapeutic inter-
vention to the orthosteric non-selective mGluR2,-3 agonists.  
GROUP III  
mGluR4, 6, 7, 8 NAMs 
  Compared to the Group I and II mGluR, the pharmacology of 
the Group III is the least developed with a lack of subtype selective 
negative modulators. To our knowledge, only one series of com-
pounds claimed in a patent (WO02102807; EP1408042 A1) has 
been described. Within this series compound 23 is described as a 
selective allosteric negative modulator of the mGluR7 with an IC50
of 7 nM.  
mGluR4 PAM 
  For the mGlu4 receptor, two compounds have been identified, 
PHCCC, 21 [29] and SIB1893, 22 [33] both originally discovered 
as antagonist for the mGlu1 and mGlu5 receptors, respectively. 
MPEP, 8 was also identified as potentiator of the mGluR4 but at 
very high concentrations (50-100 m) which are several order of 
magnitude higher than the effective concentrations needed to inhibit 
the mGlu5 receptor.  
  In rat brain slices, using CPCCC Valenti et al. [62] could dem-
onstrate that the mGlu4 receptor plays a key role in the Group III 
mGluR modulation of the excitatory transmission in the substantia 
nigra pars compacta (SNc), a key region involved in the nigral neu-
rodegeneration and the resulting movement disorders in Parkinson’s 
Disease. Unfortunately, the limiting drug-like properties of PHCCC 
and the lack of more potent and selective mGluR4 PAM prevent the 
validation in vivo in animal model of this putative use of mGluR4 
positive modulators. Additional potential pharmacotherapeutic uses 
of mGluR4 modulators have been recently reviewed by Marino et
al. [30]. 
mGluR7 PAM 
  As for the other members of the Group III receptors the lack of 
suitable selective pharmacological tools slowed considerably the 
study of the mGlu7 receptor. However, the generation and the char-
acterization of the mGluR7 knock-out mice indicated that amygdala 
dependent functions such as conditioned fear, aversive responses 
and responses to anxiety and stress related responses are altered 
[6,32,35]. 
  The recent identification of a selective allosteric agonist, 
AMN082 (24, Fig. 6) allowed the confirmation of the data obtained 
with the mGluR7 null mice [34]. In vitro, AMN082 was shown to 
potently activate the recombinantly expressed human mGlu7 recep-
tor with an EC50 of 64 nM in the absence of orthosteric agonist. In 
addition, AMN082 increases the orthosteric agonist (Glu, L-AP4) 
induced receptor activation in analogy to the positive modulators at 
the other mGluR subtypes. In vivo, AMN082 was shown to be 
orally bioavailable, to penetrate into the brain and to modulate the 
level of stress hormones (cortisol and ACTH) in wild type animal 
but not in the mGluR7 ko mouse. Taken together this data demon-
strate that mGluR7 modulation could a valuable mechanism for the 
pharmacotherapy of stress-related psychiatric disorders. 
CONCLUSIONS/OUTLOOK 
  The ubiquitous distribution of glutamate in the brain sets off the 
critical role of glutamate receptors in most major functions of the 
CNS. Next to the ionotropic glutamate-gated ion channels, me-
tabotropic glutamate receptors modulate neuronal excitability, syn-
aptic transmission, and have various metabolic functions. Albeit 
small, the Family III or Class C of G-protein-coupled receptors 
have become the focal point for the discovery of new and exciting 
modulators of glutamatergic neurotransmission. Exciting medicinal 
chemistry that allowed the interaction of small molecules with re-
ceptors through soft touched allosteric modulation that modify 
transmembrane signaling rather than compete for binding with the 
natural agonist at orthosteric sites. Indeed, the mGlu receptors are 
illustrative in the discovery of both positive and/or negative allos-
teric modulators that display a unique degree of subtype selectivity 
within the highly conserved mGlu family of receptors. The combi-
nation of these pharmacological tools, in conjunction with genetic 
approaches, has led to major advances in our understanding of the 
roles of mGlu receptors in regulating of CNS function and animal 
behavior. From cloning to the identification multiple receptors, sub-
type selective allosteric modulators and testing in double blind pla-
cebo controlled trials in less than 15 years is a remarkable story. 
These developments provide us with the unique opportunity for 
better treatments in a wide variety of neurological and psychiatric 
disorders that include complicated disease states such as depression, 
anxiety disorders, and schizophrenia. 
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